Lianbio logo

Lianbio Share Price (NASDAQ: LIAN)

▲

-4.92

(-100%)

Live

Last updated on

Bell Icon

The stock has been delisted from the stock exchange on 8 Mar 2024

Check the interactive Lianbio Stock chart to analyse performance

Lianbio Key Stats

Check Lianbio key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close
$4.92
Open
$4.96
Market Capitalization
$529.5M
Today's Volume
$171.4K
Revenue TTM
$0.0
EBITDA
$-105.3M
Earnings Per Share (EPS)
$-0.82
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-32.42%

Global Institutional Holdings in Lianbio

  • Name

    Holdings %

  • Perceptive Advisors LLC

    53.26%

  • Viking Global Investors LP

    3.30%

  • Tybourne Capital Management (HK) Ltd

    3.15%

  • Vida Ventures Advisors, LLC

    2.11%

  • 22NW, LP

    2.05%

  • TANG CAPITAL MANAGEMENT LLC

    1.67%

Analyst Recommendation on Lianbio Stock

Rating
Trend

Buy

    77%Buy

    22%Hold

    0%Sell

Based on 9 Wall street analysts offering stock ratings for Lianbio(by analysts ranked 0 to 5 stars)

About Lianbio

LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.
Organization
Lianbio
Employees
163
CEO
Mr. Konstantin Poukalov
Industry
Miscellaneous

Important FAQs about investing in LIAN Stock from India :

What is Lianbio share price today?

Lianbio share price today is as on . Lianbio share today touched a day high of {{1_rba_end}} and a low of {{1_rba_st}}.

What is the 52 week high and 52 week low for Lianbio share?

Lianbio share touched a 52 week high of {{rba_end}} and a 52 week low of {{rba_st}}. Lianbio stock price today i.e. is trending at , lower by 100% versus the 52 week high.

How to invest in Lianbio Stock (LIAN) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Lianbio on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Lianbio Shares .

What is the minimum amount required to buy Lianbio Stock (LIAN) from India?

Indian investors can start investing in Lianbio (LIAN) shares with as little as ₹90.412 or $1 (as of December 17, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹904.12 in Lianbio stock (as per the Rupee-Dollar exchange rate as on December 17, 2025). Learn more about fractional shares .

What are the returns that Lianbio has given to Indian investors in the last 5 years?

Lianbio stock has given 0.0% share price returns and 22.96% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?